Page last updated: 2024-11-10

echinacoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

echinacoside: from Buddleja species; has antihepatotoxic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
BuddlejagenusA plant genus of the family SCROPHULARIACEAE. Members contain mimengoside B, verbascoside, and phenylethanoids.[MeSH]ScrophulariaceaeThe figwort plant family of the order Lamiales. The family is characterized by bisexual flowers with tubular corollas (fused petals) that are bilaterally symmetrical (two-lips) and have four stamens in most, two of which are usually shorter.[MeSH]

Cross-References

ID SourceID
PubMed CID5281771
CHEMBL ID510539
CHEBI ID4745
SCHEMBL ID525502
MeSH IDM0167608

Synonyms (43)

Synonym
glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl o-6-deoxy-alpha-l-mannopyranosyl-(1-3)-o-(beta-d-glucopyranosyl-(1-6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), beta-d-
NCGC00091915-01
echinacoside
82854-37-3
MEGXP0_001773
2-(3,4-dihydroxyphenyl)ethyl 6-deoxy-alpha-l-mannopyranosyl-(1-3)-[beta-d-glucopyranosyl-(1-6)]-4-o-[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-d-glucopyranoside
CHEMBL510539
chebi:4745 ,
NCGC00091915-02
AC1NQZ1Q ,
[(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
NCGC00258498-01
dtxcid8013469
tox21_200945
cas-82854-37-3
dtxsid0033469 ,
i04o1dt48t ,
unii-i04o1dt48t
S3783
AKOS015897141
SCHEMBL525502
737806-07-4
echinacoside [usp-rs]
.beta.-d-glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl o-6-deoxy-.alpha.-l-mannopyranosyl-(1->3)-o-(.beta.-d-glucopyranosyl-(1->6))-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate)
CS-3400
HY-N0020
surecn525502
[(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-3-yl] (e)-3-(3,4-di
dsstox_cid_13469
mfcd00075695
echinacoside, analytical standard
echinacoside, 98% (hplc)
echinacoside, united states pharmacopeia (usp) reference standard
echinacoside, primary pharmaceutical reference standard
Q475631
(2r,3r,4r,5r,6r)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-((((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)methyl)-4-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-3-yl 3-(3,4-
DB15488
echinacoside,(s)
A12039
HMS3885K04
CCG-270479
AS-56376
AC-34699

Research Excerpts

Overview

Echinacoside (ECH) is a phenylethanoid extracted from the stems of Cistanches salsa, an herb used in Chinese medicine formulations. It is effective against glioblastoma multiforme (GBM) EchinACoside is a natural anti-cancer compound and is of great valor.

ExcerptReferenceRelevance
"Echinacoside is a group of natural compounds extracted from medicinal plants Cistanche and Echinacea, which has neuroprotective, antiaging, immunomodulatory and anticancer effects, but its specific role and mechanism in tumor remains partially unclear. "( Echinacoside inhibits the proliferation, migration, invasion and angiogenesis of ovarian cancer cells through PI3K/AKT pathway.
Lei, P; Liu, J; Liu, N; Tang, N; Wang, F, 2022
)
3.61
"Echinacoside (ECH) is a major natural bioactive ingredient derived from Cistanches Herba and Echinacea that has a variety of pharmacological effects."( Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification.
Shi, R; Shu, W; Wang, H; Wang, Z; Zhang, J; Zhang, W; Zhao, R, 2022
)
1.69
"Echinacoside (ECH) is a phenylethanoid extracted from the stems of Cistanches salsa, an herb used in Chinese medicine formulations, and is effective against glioblastoma multiforme (GBM). "( Echinacoside (ECH) suppresses proliferation, migration, and invasion of human glioblastoma cells by inhibiting Skp2-triggered epithelial-mesenchymal transition (EMT).
Chen, C; Chen, D; Deng, Y; Huang, H; Liu, S; Qin, Y; Shi, S; Wang, Z; Wu, Y; Yin, J; Yu, H; Zou, D, 2022
)
3.61
"Echinacoside (ECH) is a natural phenylethanoid glycoside and is the major active component of traditional Chinese medicine Cistanches Herba, which is reported to possess powerful anti-oxidation and anti-inflammatory effects."( Echinacoside inhibited cardiomyocyte pyroptosis and improved heart function of HF rats induced by isoproterenol via suppressing NADPH/ROS/ER stress.
Bai, H; Duan, Y; Luan, C; Ni, Y; Zhang, J; Zhu, W, 2022
)
2.89
"Echinacoside (ECH) is a natural bioactive component with antioxidant, anti-inflammatory, anti-apoptosis, and anti-tumor properties. "( Echinacoside ameliorates 5-fluorouracil-induced endothelial injury and senescence through SIRT1 activation.
Li, X; Li, Y; Ning, Z; Wu, Y, 2023
)
3.8
"Echinacoside (ECH) is a natural anti-cancer compound and is of great value in cancer treatment. "( Echinacoside regulates PI3K/AKT/HIF-1α/VEGF cross signaling axis in proliferation and apoptosis of breast cancer.
Li, J; Liang, H; Liu, X; Liu, Z; Shi, G; Yin, G, 2024
)
4.33
"Echinacoside (ECH) is a phenylethanoid glycoside possessing prominent anti-inflammatory effects and various neuroprotective properties in the central nervous system, but the effect of ECH on SCI was rarely studied."( Ameliorative effects of echinacoside against spinal cord injury via inhibiting NLRP3 inflammasome signaling pathway.
Deng, Q; Gao, S; Guo, H; Liang, W; Sheng, W; Xu, T; Xun, C, 2019
)
1.54
"Echinacoside (ECH) is a natural compound with an endothelium‑dependent vasodilatory effect. "( Echinacoside‑induced nitric oxide production in endothelial cells: Roles of androgen receptor and the PI3K‑Akt pathway.
Gu, J; Gu, L; Lian, D; Liu, X; Zheng, Y; Zhou, W, 2020
)
3.44
"Echinacoside (ECH) is a phenylethanoid glycoside from the Cistanche genus, which possesses strong antiapoptosis and neuroprotective activities."( Echinacoside promotes the proliferation of human renal tubular epithelial cells by blocking the HBX/TREM2‑mediated NF‑κB signalling pathway.
Gong, D; Wang, L; Wu, Q; Zhang, Y; Zhong, L, 2020
)
2.72
"Echinacoside is a phenylethanoid glycoside from Tibetan herbs known for its vasorelaxant effect and for inhibiting the proliferation of rat pulmonary arterial smooth muscle cells."( Echinacoside prevents hypoxic pulmonary hypertension by regulating the pulmonary artery function.
Bao, Y; Cairang, N; Gai, X; Gazang, Z; He, Y; Li, Z; Liang, Y; Lin, P; Lu, D; Ma, Y; Wu, X; Zuo, M, 2020
)
2.72
"Echinacoside (ECH) is a natural compound extracted from the stem of the Cistanche deserticola plant, has significant biological properties, including antioxidant, anti-inflammatory, neuroprotective, anti-tumor, hepatoprotective, and immunomodulatory properties. "( Echinacoside improves diabetic liver injury by regulating the AMPK/SIRT1 signaling pathway in db/db mice.
Hao, Y; Liao, M; Yang, L; Zhang, X, 2021
)
3.51
"Echinacoside is a phenylethanoid glycoside and possesses neuroprotective activity in vitro and in vivo. "( Echinacoside ameliorates the memory impairment and cholinergic deficit induced by amyloid beta peptides via the inhibition of amyloid deposition and toxicology.
Lin, HC; Shiao, YJ; Su, MH; Wu, CR, 2017
)
3.34
"Echinacoside (ECH) is a phenylethanoid glycoside that possesses various activities, including anti-inflammatory effect."( Echinacoside alleviated LPS-induced cell apoptosis and inflammation in rat intestine epithelial cells by inhibiting the mTOR/STAT3 pathway.
Han, B; Li, L; Wan, G; Zhang, Z, 2018
)
2.64
"Echinacoside (ECH) is a phenylethanoid glycoside extracted from a Chinese herbal medicine, Cistanches salsa. "( Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells.
Ni, J; Song, Y; Wang, G; Xia, W; Ye, Y; Zhuang, J, 2019
)
2.27
"Echinacoside is a major compound of Cistanche Herb and has glutamate release-inhibiting activity in the brain. "( Echinacoside, an Active Constituent of Cistanche Herba, Exerts a Neuroprotective Effect in a Kainic Acid Rat Model by Inhibiting Inflammatory Processes and Activating the Akt/GSK3β Pathway.
Hsieh, HL; Hsieh, TY; Huang, SK; Lin, TY; Lu, CW; Wang, SJ, 2018
)
3.37
"Echinacoside (ECH) is a major bioactive phenyethanoids in medicinal herba Cistanche and has been reported to have antiinflammatory activity and beneficial effect on wound healing in many experimental studies. "( Amelioration of dextran sulphate sodium-induced colitis in mice by echinacoside-enriched extract of Cistanche tubulosa.
Du, C; Guan, Q; Guo, Y; Jia, Y; Jiang, Y; Salh, B; Tu, P, 2014
)
2.08
"Echinacoside is a natural compound with potent reactive oxygen species (ROS)-scavenging and anti-oxidative bioactivities, which protect cells from oxidative damages. "( Echinacoside Induces Apoptosis in Human SW480 Colorectal Cancer Cells by Induction of Oxidative DNA Damages.
Dong, L; Niu, J; Wang, H; Wang, Y; Wu, N; Yu, D; Zou, Z, 2015
)
3.3
"Echinacoside is an important bioactive compound extracted from Cistanche tubulosa which was endangered by overexploitation. "( Separation and purification of echinacoside from Penstemon barbatus (Can.) Roth by recycling high-speed counter-current chromatography.
Deng, J; Su, J; Tan, F; Xie, J, 2010
)
2.09
"Echinacoside is a caffeoyl conjugate of Echinacea with known anti-hyaluronidase properties."( Investigation of anti-hyaluronidase treatment on vocal fold wound healing.
Bless, DM; Lim, X; Munoz-del-Rio, A; Rousseau, B; Tateya, I, 2006
)
1.06

Effects

ExcerptReferenceRelevance
"Echinacoside (ECH) has been shown to possess a multitude of pharmacological activities, however, oral administered ECH failed to fulfill its therapeutic potential due to poor absorption and low bioavailability. "( Phospholipid complex as an approach for bioavailability enhancement of echinacoside.
Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2015
)
2.09

Treatment

ExcerptReferenceRelevance
"Echinacoside treatment significantly reduced tumor growth, which was accompanied by a reduction in Wnt/β-catenin signaling."( Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway.
Gong, L; Qiu, K; Tang, C; Wan, L; Zhang, Z, 2020
)
2.72

Pharmacokinetics

The validated method has been successfully applied for pharmacokinetic studies of echinacoside in Parkinson's disease (PD) rat plasma after oral administration.

ExcerptReferenceRelevance
" The method was successfully applied to a pharmacokinetic study in rats after an intragastric administration of echinacoside (100 mg/kg)."( A sensitive and specific liquid chromatography/tandem mass spectrometry method for determination of echinacoside and its pharmacokinetic application in rats.
Dai, L; Hao, H; Jiang, Y; Tu, P; Wang, G; Wang, Q; Wang, Y; Yang, H; Zhang, Y; Zheng, C, 2009
)
0.78
" The validated method has been successfully applied for pharmacokinetic studies of echinacoside in Parkinson's disease (PD) rat plasma after oral administration."( Application of two-phase hollow fiber liquid phase microextraction coupled with high-performance liquid chromatography for the study of the echinacoside pharmacokinetics in Parkinson's disease rat plasma.
Sun, JB; Wang, FQ; Zeng, P; Zhang, Q; Zhou, J,
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of this study was to establish and verify the model of osteoporosis combined with Alzheimer's disease in rat, and to investigate the double effects of echinacoside and acteoside on this concurrent model."( Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa.
Chen, Y; Fang, JY; Li, F; Li, P; Li, YQ, 2020
)
0.96
"The model of osteoporosis combined with Alzheimer's disease in rat was feasible and successfully established."( Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa.
Chen, Y; Fang, JY; Li, F; Li, P; Li, YQ, 2020
)
0.76

Bioavailability

Echinacoside (ECH) is a phenylethanoid glycoside isolated from Chinese herbal medicine, Cistanche salsa. It can inhibit HCC progression; however, poor absorption and low bioavailability limit its biological applications.

ExcerptReferenceRelevance
" The assay method was successfully applied to the study of the pharmacokinetics and bioavailability of ECH in rat."( Determination of echinacoside in rat serum by reversed-phase high-performance liquid chromatography with ultraviolet detection and its application to pharmacokinetics and bioavailability.
Chen, J; Jia, C; Li, Y; Shi, H; Tu, P; Wu, X, 2006
)
0.67
"The aim of this study was to formulate ECH into phospholipid complex (phytosome, PHY) to enhance intestinal absorption and oral bioavailability of ECH in vivo."( Phospholipid complex as an approach for bioavailability enhancement of echinacoside.
Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2015
)
0.65
"The PHY was prepared by a solvent evaporation method and was characterized by differential scanning calorimetry (DSC) and infrared spectroscopy (IR), and then the physicochemical properties, intestinal absorption and bioavailability of the PHY were investigated."( Phospholipid complex as an approach for bioavailability enhancement of echinacoside.
Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2015
)
0.65
"Compared with ECH alone or the MIX group, the relative bioavailability of ECH was increased significantly after formulation into PHY (p < 0."( Phospholipid complex as an approach for bioavailability enhancement of echinacoside.
Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2015
)
0.65
" However, the extremely low oral bioavailability of ECH in rats implies that ECH may go through multiple hydrolysis steps in the gastrointestinal tract prior to its absorption into the blood."( Identification of Echinacoside Metabolites Produced by Human Intestinal Bacteria Using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry.
Li, X; Li, Y; Tu, P; Xing, S; Zhou, G, 2015
)
0.75
"This present study investigated the absorption kinetics of echinacoside (ECH) in situ and in vitro and its oral bioavailability in rats."( Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil.
Kou, JP; Li, F; Shen, JY; Yang, XL; Yang, ZL, 2015
)
0.91
" Pharmacokinetics study was performed to investigate the influences of verapamil and clove oil on ECH bioavailability in vivo."( Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil.
Kou, JP; Li, F; Shen, JY; Yang, XL; Yang, ZL, 2015
)
0.67
"The absorption and bioavailability of ECH were enhanced by verapamil and clove oil, respectively, both in vitro and in vivo."( Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil.
Kou, JP; Li, F; Shen, JY; Yang, XL; Yang, ZL, 2015
)
0.67
" Echinacoside (ECH), a phenylethanoid glycoside isolated from Chinese herbal medicine, Cistanche salsa, can inhibit HCC progression; however, poor absorption and low bioavailability limit its biological applications."( Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Ma, X; Mai, Z; Song, Y; Wang, G; Wang, M; Xia, W; Ye, Y; Zhang, M; Zhou, B, 2022
)
1.86
" Given that ECH has an extremely low bioavailability and gut microbiota drives the CRC progression, we hypothesized that ECH could inhibit metastatic CRC by targeting the gut microbiome."( Echinacoside inhibits colorectal cancer metastasis via modulating the gut microbiota and suppressing the PI3K/AKT signaling pathway.
He, F; Hou, X; Hu, L; Jia, F; Wei, J; Yuan, F; Yuan, Y; Zhao, L; Zheng, Z, 2024
)
2.89
" Several crucial concerns surfaced, encompassing the recognition of active metabolites that exhibited inadequate bioavailability in their prototype form, the establishment of precise molecular signal pathways or targets associated with the aforementioned effects of echinacoside, and the scarcity of dependable clinical trials."( Echinacoside: A promising active natural products and pharmacological agents.
Jiang, S; Wang, W; Zhao, Y; Zhu, G, 2023
)
2.53

Dosage Studied

ExcerptRelevanceReference
" Thus, there is a pressing need to develop a new oral dosage form to enhance its intestinal absorption and improve bioavailability."( Phospholipid complex as an approach for bioavailability enhancement of echinacoside.
Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2015
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oligosaccharideA compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency1.04770.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency1.04770.025120.237639.8107AID886; AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency68.67010.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
15-lipoxygenase, partialHomo sapiens (human)Potency0.50120.012610.691788.5700AID887
AR proteinHomo sapiens (human)Potency37.90830.000221.22318,912.5098AID1259243; AID1259381
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
progesterone receptorHomo sapiens (human)Potency0.09370.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.40740.003041.611522,387.1992AID1159552; AID1159555
Histone H2A.xCricetulus griseus (Chinese hamster)Potency48.85110.039147.5451146.8240AID1224845
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.06640.000627.21521,122.0200AID743202; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (165)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.61)18.7374
1990's3 (1.82)18.2507
2000's35 (21.21)29.6817
2010's84 (50.91)24.3611
2020's42 (25.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.36 (24.57)
Research Supply Index5.14 (2.92)
Research Growth Index5.67 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (29.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.96%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other164 (97.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]